Recent advances in the management of Duchenne muscular dystrophy

Archives of Disease in Childhood

Volumn 100, Issue 12, 2015, Pages 1173-1177

  Strehle, Eugen Matthias ^a   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATALUREN; CREATINE KINASE; DRISAPERSEN; DYSTROPHIN; ETEPLIRSEN; GLUCOCORTICOID; LISINOPRIL; LOSARTAN; MICRORNA;

CLINICAL RESEARCH; CREATINE KINASE BLOOD LEVEL; DRUG COST; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE THERAPY; GENETIC SCREENING; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; CHILD; DISEASE MANAGEMENT; LONG TERM CARE; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PARENT; PROCEDURES;

CHILD; DISEASE MANAGEMENT; HUMANS; LONG-TERM CARE; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PARENTS;

EID: 84949097667     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-307962     Document Type: Review

References (65)

1. Emery AE, Emery ML. Edward Meryon (1809-1880) and muscular dystrophy. J Med Genet 1993;30:506-11.
2. Rondot PGBA. Duchenne de Boulogne (1806-1875). J Neurol 2005;252:866-7.
3. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954;77:169-231.
4. Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;158:3175-86.
5. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93:986-90.
6. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 2012;31:121-5.
7. Quinlivan R. Early diagnosis of Duchenne muscular dystrophy is essential improve long term outcomes. Arch Dis Child 2014;99:1061.
8. Van Ruiten HJ, Straub V, Bushby K, et al. Improving recognition of Duchenne muscular dystrophy: A retrospective case note review. Arch Dis Child 2014;99:1074-7.
9. Scully MA, Farrell PM, Ciafaloni E, et al. Cystic fibrosis newborn screening: A model for neuromuscular disease screening? Ann Neurol 2015;77:189-97.
10. Hoffman EP. Dystrophinopathies. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of voluntary muscle. 7th edn. Cambridge: Cambridge University Press, 2001:385-432.
11. Kunkel LM. 2004 William Allen Award address. Cloning of the DMD gene. Am J Hum Genet 2005;76:205-14.
12. Sinnreich M. Dystrophinopathies. In: Karpati G, Hilton-Jones D, Bushby K, Griggs RC, eds. Disorders of voluntary muscle. 8th edn. Cambridge: Cambridge University Press, 2010:205-29.
13. Dubowitz V. Muscular dystrophy and related disorders. Postgrad Med J 1965;41:332-46.
14. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychological management. Lancet Neurol 2010;9:77-93.
15. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-89.
16. Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol 2012;31:9-15.
17. Flanigan KM, Campbell K, Viollet L, et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 2013;24:797-806.
18. Ricotti V, Ridout DA, Scott E, et al. Long-Term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013;84:698-705.
19. Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 2013;48:27-31.
20. Gordon KE, Dooley JM, Sheppard KM, et al. Impact of biphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 2011;127:e353-8.
21. Duckworth AD, Mitchell MJ, Tsinkos AI. Incidence and risk factors for post-operative complications after scoliosis surgery in patients with Duchenne muscular dystrophy: A comparison with other neuromuscular conditions. Bone Joint J 2014;96:943-9.
22. Ashwath ML, Jacobs IB, Crowe CA, et al. Left ventricular dysfunction in Duchenne muscular dystrophy and genotype. Am J Cardiol 2014;114:284-9.
23. Allen HD, Flanigan KM, Thrush PT, et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr 2013;5.
24. Politano L, Nigro G. Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol 2012;31:24-30.
25. Matsumara T. Beta-blockers in children with Duchenne muscular dystrophy. Rev Recent Clin Trials 2014.
26. Blain A, Greally E, Laval S, et al. Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy. PLoS ONE 2013;8:e57260.
27. Janssen PM, Murray JD, Schill KE, et al. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS ONE 2014;9:e88360.
28. Iodice F, Testa G, Averardi M, et al. Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy with end stage cardiac failure: Management and lessons learned. Neuromuscul Disord 2015;25:19-23.
29. Bothwell JE, Dooley JM, Gordon KE, et al. Duchenne muscular dystrophy-parental perceptions. Clin Pediatr (Phila) 2002;41:105-9.
30. Rahbek J, Werge B, Madsen A, et al. Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil 2005;8:17-28.
31. Pangalila RF, van den Bos GA, Bartels B, et al. Quality of life of adult men with Duchenne muscular dystrophy in the Netherlands: implications for care. J Rehabil Med 2015;47:161-6.
32. Pangalila RF, van den Bos GA, Bartels B, et al. Prevalence of fatigue, pain, and affective disorders in adults with Duchenne muscular dystrophy and their associations with quality of life. Arch Phys Med Rehabil 2015. Published Online First. doi:10.1016/j.apmr.2015.02.012
33. Nozoe KT, Polesel DN, Moreira GA, et al. Sleep quality of mother-caregivers of Duchenne muscular dystrophy patients. Sleep Breath 2015. Published Online First.
34. Mayhew A, Cano S, Scott E, et al. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011;53:534-42.
35. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD Global Database: Analysis of more than 7000 Duchenne muscular dystrophy mutations. Hum Mutat 2015;36:395-402.
36. Spurney C, Shimizu R, Morgenroth LP, et al. Cooperative International Neuromuscular Research Group Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 2014;50:250-6.
37. Landfeldt E, Lindgren P, Bell CF, et al. Compliance to care guidelines for Duchenne muscular dystrophy. J Neuromuscul Dis 2015;2:63-72.
38. Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin 2014;32:671-88.
39. Peltz SW, Morsy M, Welch EM, et al. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 2013;64:407-25.
40. McElroy SP, Nomura T, Torrie SL, et al. A lack of premature termination codon read-Through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 2013;11:e1001593.
41. Ryan NJ. Ataluren: first global approval. Drugs 2014;74:1709-14.
42. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50:477-87.
43. Wood MJ. To skip or not to skip: That is the question for Duchenne muscular dystrophy. Mol Ther 2013;21:2131-2.
44. Findlay AR, Wein N, Kaminoh, et al. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45. Ann Neurol 2015;77:668-74.
45. Flanigan KM, Voit T, Rosales XQ, et al. Pharmacokinetics and safety of single doses of drisapersen in non-Ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 2014;24:16-24.
46. Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): An exploratory, randomised placebo-controlled phase 2 study. Lancet Neurol 2014;13:987-96.
47. Ruegg UT. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 2013;26:577-84.
48. Cirak S, Feng L, Anthony K, et al. Restoration of the dystrophin-Associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012;20:462-7.
49. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013;74:637-47.
50. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (London) 2011;1:1217-35.
51. Goemans N, Klingels K, van den Hauwe M, et al. Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS ONE 2013;8:e84120.
52. McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study-A longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013;48:32-54.
53. Shklyar I, Geisbush TR, Mijialovic AS, et al. Qualitative muscle ultrasound in Duchenne muscular dystrophy: A comparison of techniques. Muscle Nerve 2015;51:207-13.
54. Forbes SC, Wilcocks RJ, Triplett WT, et al. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: A multicentre cross sectional study. PLosS ONE 2014;9:e106435.
55. Kinali M, Arechavala-Gomeza V, Cirak S, et al. Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 2011;25:346-53.
56. Dubowitz V, Sewry CA, Olfors A. Muscle biopsy: A practical approach. 4th edn. Philadelphia: Saunders Ltd, 2013.
57. Lynn S, Aartsma-Rus A, Bushby K, et al. Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord 2015;25:96-105.
58. Alexander MS, Kunkel LM. Skeletal muscle microRNAs: Their diagnostic and therapeutic potential in human muscle diseases. J Neuromuscul Dis 2015;2:1-11.
59. Appleby J. Spending on health and social care over the next 50 years. Why think long term? London: The Kings Fund, 2013.
60. Jones NM, Charlesworth A. The anatomy of health spending 2011/2012. London: Nuffield Trust, 2013.
61. Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis 2014;9:210.
62. Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy: An international cross-sectional study. Neurology 2014;83:529-36.
63. Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 2013;14:373-8.
64. Al-Zaidy S, Rodino-Klapac L, Mendell JR. Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol 2014;51:607-18.
65. Strehle EM. Long-Term management of children with neuromuscular disorders. J Pediatr (Rio J) 2009;85:379-84.